ClinicalTrials.gg
Active, not recruitingNCT06847854PregondaUpdated Sep 2, 2026

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)

A Phase 1 interventional study of RO7497372 in Diabetic Macular Edema, sponsored by Genentech, Inc.. Active, not recruiting at 38 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Dec 2022, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 28 studies in Macular Edema by Hoffmann-La Roche — 1 open to participants now, 5 under way, 1 of them phase 3. Macular Edema · Hoffmann-La Roche.

Enrollment
20th of 25
151 · median 377
Started
2022
with 3 others
Phase 1
3 of 28
1 open now
Registered
26th of 28
by date

Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 20th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2022, is one of 3 in phase 1, and was the 26th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 28 studies in Macular Edema by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Macular Edema by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 is to provide data for RO7497372 safety and tolerability, as well as to characterize the ocular and systemic pharmacokinetics (PK), systemic anti-drug antibodies (ADA), and duration of target engagement, i.e., the pharmacodynamics (PD) in aqueous humor (AH) and blood. Part 2 will evaluate the safety, tolerability, PK, and PD of two dose strengths of RO7497372 (low dose and high dose), identified as safe and tolerated in Part 1.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of diabetes mellitus (type 1 or type 2), as defined by the world health organization (WHO) and/or American Diabetes Association
  • Participant consents to AH collection
  • Collection of > 90 microlitres (µL) AH (at each visit required per schedule of activities [SoA]) if deemed feasible and safe by the Investigator.
  • Macular thickening secondary to DME involving the center of the fovea with CST >= 325 µm at screening
  • Decreased BCVA primarily due to DME with ETDRS score of 78 to 19 letters (both inclusive) at screening
  • Adequately clear ocular media and adequate pupillary dilation to allow acquisition of good quality retinal images
  • Diagnosis of non-proliferative DR
  • Treatment-naive and Pre-treated participants after washout

Exclusion criteria

Exclusion Criteria:

  • Any major illness or major surgical procedure ≤ 4 weeks before Day 1
  • Any febrile illness and associated sequelae ≤ 1 week prior to Day 1
  • Active cancer ≤ 1 year prior to Day 1
  • Cerebral vascular accident (including stroke and ) or myocardial infarction ≤ 24 weeks prior to Day 1
  • ≥ 12% at screening
  • Any panretinal photocoagulation or macular laser photocoagulation treatment prior to Day 1
  • History of vitreoretinal surgery/pars plana vitrectomy
  • Any cataract surgery within 12 weeks prior to Day 1 or any planned surgery during the study
  • History of any glaucoma surgery including laser glaucoma procedures
  • Uncontrolled glaucoma
  • Any active intra- or periocular infection on Day 1
  • Any active or history of Intraocular inflammation
  • Intravitreal treatment with an anti-IL-6 (e.g., vamikibart) or anti-IL-6 receptor treatment at any time
  • Any proliferative DR
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Part 1: Multiple Ascending Dose

    Participants will receive multiple ascending doses of RO7497372, 3 times every 4 weeks (Q4W) as an IVT injection up to Week 8 in the study eye.

    Drug: RO7497372

  • Experimental
    Part 2: RO7497372 Low Dose

    Participants will receive 6 doses of RO7497372, low dose, Q4W followed by 3 doses, every eight weeks (Q8W) as an IVT injection up to Week 44 in the study eye.

    Drug: RO7497372

  • Experimental
    Part 2: RO7497372 High Dose

    Participants will receive 6 doses of RO7497372, high dose, Q4W followed by 3 doses, Q8W as an IVT injection up to Week 44 in the study eye. Treatment in this arm has been discontinued due to the Sponsor's decision.

    Drug: RO7497372

Interventions

  • DrugRO7497372

    RO7497372 will be administered as IVT injection as per the schedule specified in the arms.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Adverse Events (AEs)

    Time frame: Up to 28 Weeks

  2. Part 2: Number of Participants With Intraocular Inflammation (IOI) AEs as Reported by the Investigator

    Time frame: Baseline to Week 48

  3. Part 2: Number of Participants With Severe or Serious Drug-Related IOI AEs

    Number of participants with severe or serious drug-related IOI AEs severity will be determined according to the DAIDS toxicity grading scale as reported by the Investigator.

    Time frame: Baseline to Week 48

  4. Part 2: Number of Participants With Occlusive Retinal Vasculitis AEs as Reported by the Investigator

    Time frame: Baseline to Week 48

Secondary outcomes

  1. Part 1: Concentration of RO7497372 in Blood

    Time frame: Up to Week 28

  2. Part 1: Concentration of RO7497372 in Aqueous Humor (AH)

    Time frame: Up to Week 28

  3. Part 2: Number of Participants With AEs

    Number of participants with AEs severity determined according to the DAIDS toxicity grading scale.

    Time frame: Up to 56 weeks

  4. Part 2: Number of Participants With Persistent Treatment-induced Anti-drug Antibody (ADAs)

    Time frame: Up to 56 weeks

  5. Part 2: Concentration of RO7497372 in AH

    Time frame: Up to Week 56

  6. Part 2: Concentration of RO7497372 in Plasma

    Time frame: Up to Week 56

  7. Part 2: Change From Baseline in Best Corrected Visual Acuity (BCVA) Score Over Time

    BCVA will be measured via Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters using a set of three Precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity (VA) examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicates improvement in VA.

    Time frame: From Baseline (Day 1) up to Week 56

  8. Part 2: Absolute Value of BCVA Score Over Time

    BCVA will be measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicates improvement in VA.

    Time frame: Up to Week 56

  9. Part 2: Percentage of Participants Gaining ≥ 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA From Baseline Over Time

    BCVA will be measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicates improvement in VA.

    Time frame: Up to Week 56

  10. Part 2: Percentage of Participants Avoiding a Loss of ≥ 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA From Baseline Over Time

    BCVA will be measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicates improvement in VA.

    Time frame: Up to Week 56

  11. Part 2: Change From Baseline in Central Subfield Thickness (CST) Over Time

    CST is defined as the average thickness of the central 1-mm circle of the ETDRS grid centered to the fovea measured between the internal limiting membrane and the Bruch's membrane. CST will be determined by CRC evaluation of SD-OCT images.

    Time frame: From Baseline (Day 1) up to Week 56

  12. Part 2: Absolute Value of CST Over Time

    CST is defined as the average thickness of the central 1-mm circle of the ETDRS grid centered to the fovea measured between the internal limiting membrane and the Bruch's membrane. CST will be determined by CRC evaluation of SD-OCT images.

    Time frame: Up to Week 56

  13. Part 2: Percentage of Participants With Absence of DME Over Time

    Absence of DME is defined as CST \< 325 micrometre (μm) by spectral domain optical coherence tomography (SD-OCT).

    Time frame: Up to Week 56

  14. Part 2: Percentage of Participants With Absence of Intraretinal Fluid and/or Subretinal Fluid Over Time

    Presence of intraretinal and subretinal fluid will be determined by CRC evaluation of SD -OCT images.

    Time frame: Up to Week 56

  15. Part 2: Percentage of Participants With ≥ 2-step Diabetic Retinopathy Severity Scale (DRSS) Improvement From Baseline on the ETDRS DRSS Over Time

    The DRSS will be graded according to ETDRS grading schedules from report 18 JOVS, February 1998, Vol. 39, No. 2. ETDRS DRSS is 13 step scale which measures severity of diabetic retinopathy (DR). The DRSS scores vary from 10 (DR absent) to 90 (ungradable proliferative diabetic retinopathy(PDR)). Higher levels indicate higher severity.

    Time frame: Up to Week 56

07

Study locations

38 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Nov 2026, 47 months after the start.

Of 25 phase 1 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's planned 47 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Feb 26, 2025
StartActual
Dec 8, 2022
Primary completionEst.
Nov 16, 2026
CompletionEst.
Jan 18, 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06847854
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Dec 8, 2022
Primary completion
Nov 16, 2026 (estimated)
Completion
Jan 18, 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion